Non-intensive treatment for adults with Ph-negative acute lymphoblastic leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a non-intensive treatment approach for adult patients with Ph-negative acute lymphoblastic leukemia (ALL) who are in complete remission but have minimal residual disease (MRD). The treatment involves a combination of venetoclax for T-cell ALL and blinatumomab for B-cell ALL, along with a structured regimen of intrathecal injections and maintenance therapy. The study aims to monitor MRD status closely and adjust treatment based on patient response, potentially avoiding more aggressive interventions like hematopoietic stem cell transplantation for certain patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

• age 18-55 years old of patient,

\- Clinical diagnosis of non-treated Ph-negative ALL

Exclusion Criteria:

• age more than 55 years old,

* Clinical diagnosis of Ph-positive ALL
* Clinical diagnosis of relapsed/refractory ALL,

Where it's running

• Olga Aleshina
  Moscow, Russia Recruiting

Study contacts

• Study coordinator: Olga Aleshina, MD, PhD
• Email: dr.gavrilina@mail.ru
• Phone: +79629745058

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Virtual buddy movement program to improve motor and social skills in children in remission from leukemia

  This 12-week program will test whether virtual buddy-led movement therapy helps children aged 5–12 in remission from precursor cell lymphoblastic leukemia improve motor skills and social interaction.

  Recruiting Comenius University · Bratislava · NCT07522905

• Electronic mindfulness-based music therapy for patients receiving stem cell transplantation

  This trial tests an eHealth mindfulness-based music therapy to see if it improves quality of life and reduces symptoms for adults undergoing stem cell transplantation.

  Recruiting University of Miami · Miami, Florida · NCT07469592

• Phase I CAR T-cell therapy for relapsed or refractory acute lymphoblastic leukemia in children, adolescents, and young adults

  This phase I study will test two CAR T-cell approaches to see if they are safe and feasible for children and young adults with relapsed or refractory B-ALL or T-ALL.

  Recruiting Phase 1 Instituto de Investigación Hospital Universitario La Paz · Madrid, Madrid · NCT06709469

• Combining low-dose chemotherapy with immuno-targeted drugs for elderly patients with Ph-negative B-ALL

  This study is testing a new treatment that combines low-dose chemotherapy with targeted drugs to see if it can help older patients with a specific type of leukemia feel better and stay in remission longer.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06387121

• Combining a pediatric treatment approach with Venetoclax for young and adult patients with a specific type of leukemia

  This study is testing a new treatment plan that combines a pediatric approach with Venetoclax to see if it helps teenagers and adults with a specific type of leukemia achieve better recovery and reduce the chance of relapse.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT05660473

• Testing TURALIO(R) for treating hard-to-treat cancers in young people

  This study is testing if TURALIO(R) can safely help children and young adults with tough-to-treat cancers by seeing how well it works to shrink tumors or stop them from growing.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT02390752

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.